当前位置: X-MOL 学术Biomaterials › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Nanovaccine biomineralization for cancer immunotherapy: a NADPH oxidase‐inspired strategy for improving antigen cross-presentation via lipid peroxidation
Biomaterials ( IF 12.8 ) Pub Date : 2021-08-25 , DOI: 10.1016/j.biomaterials.2021.121089
Runping Su 1 , Gaowei Chong 1 , Haiqing Dong 1 , Jingjing Gu 1 , Jie Zang 1 , Ruiqing He 1 , Juanjuan Sun 1 , Tingting Zhang 1 , Yuge Zhao 1 , Xiao Zheng 1 , Yan Yang 1 , Yan Li 1 , Yongyong Li 1
Affiliation  

Current efforts to develop novel vaccine nanotechnologies to increase cytotoxic T lymphocytes have met the challenges of the limited efficacy of antigen cross-presentation. Recent studies have uncovered a unique biological mechanism by which activation of the NADPH oxidase 2 (NOX2) complex, a major source of reactive oxygen species (ROS), enhances the cross-presentation by antigen-presenting cells (APCs). Inspired by the NOX2 mechanism, we devise biomineralized nanovaccines named NVscp, which are developed by in situ growth of calcium peroxide on nanovaccines self-assembled with the model antigen ovalbumin. The ~80 nm NVscp efficiently flow to the draining lymph nodes, where they accumulate within APC endo-/lysosomes, and generate a rapid burst of ROS in response to the acidic endo-/lysosomal environment with the subsequent endo-/lysosomal lipid peroxidation. Accompanied by the process, NVscp stimulate distinct APCs maturation and antigen presentation to T lymphocytes. Notably, high levels of antigen-specific CD8+ T cell responses, accompanied by the induction of CD4+ T helper cells, are achieved. More importantly, NVscp significantly increase the ratios of intratumoral CD8+ T/regulatory T cells and achieve prominent tumor therapy effects. The NOX2-inspired biomineralized NVscp represent an effective and easily applicable strategy that enables the strong cross-presentation of exogenous vaccine antigens.



中文翻译:

用于癌症免疫治疗的纳米疫苗生物矿化:一种 NADPH 氧化酶启发的通过脂质过氧化改善抗原交叉呈递的策略

目前开发新型疫苗纳米技术以增加细胞毒性T 淋巴细胞的努力已经遇到了抗原交叉呈递效力有限的挑战。最近的研究揭示了一种独特的生物学机制,通过该机制,活性氧 (ROS) 的主要来源 NADPH 氧化酶 2 (NOX2) 复合物的激活增强了抗原呈递细胞 (APC) 的交叉呈递。受 NOX2 机制的启发,我们设计了名为 NVs cp 的生物矿化纳米疫苗,该疫苗是通过在与模型抗原卵清蛋白自组装的纳米疫苗上原位生长过氧化钙而开发的~80 nm NVs cp有效地流向引流淋巴结,它们在 APC 内/溶酶体中积累,并产生快速爆发的 ROS 以响应酸性内/溶酶体环境以及随后的内/溶酶体脂质过氧化。伴随着这个过程,NVs cp刺激不同的 APCs 成熟和抗原呈递给 T 淋巴细胞。值得注意的是,实现了高水平的抗原特异性 CD8 + T 细胞反应,伴随着 CD4 + T 辅助细胞的诱导更重要的是,NVs cp显着增加了肿瘤内 CD8 + T/调节性 T 细胞的比例,并取得了显着的肿瘤治疗效果。受 NOX2 启发的生物矿化 NVs cp 代表了一种有效且易于应用的策略,可以实现外源疫苗抗原的强交叉呈递。

更新日期:2021-09-01
down
wechat
bug